J Clin Oncol:大多数2-3级宫颈上皮内瘤变(CIN2/3)不需要治疗

2022-05-12 Nebula MedSci原创

宫颈筛查可通过检测和治疗 2 级或 3 级宫颈上皮内瘤变 (CIN2/3) 来预防宫颈癌。但是,筛查也会导致过度医疗,因为部分 CIN 2/3 病变在不治疗的情况下也可自发消退。

宫颈筛查可通过检测和治疗 2 级或 3 级宫颈上皮内瘤变 (CIN2/3) 来预防宫颈癌。但是,筛查也会导致过度医疗,因为部分 CIN 2/3 病变在不治疗的情况下也可自发消退。

本研究是一项多中心的纵向队列研究,目的是在未治疗的 CIN 2/3 女性中评估FAM19A4/miR124-2 甲基化对 CIN2/3 临床转归的预测意义。

研究人员对患有 CIN2/3 的女性进行了 24 个月的前瞻性随访。用观察代替手术切除。通过基线时收集的样本检测 FAM19A4/miR124-2 甲基化。每 6 个月进行一次人乳头瘤病毒 (HPV) 检测和细胞学检查,并进行阴道镜检查以排除 CIN 进展。最后一次随访时,进行两次活检。临床消退定义:经组织学证实不存在 CIN2+ 或 HPV 阴性且细胞学正常。


根据基线FAM19A4/miR124-2 甲基化分层的临床消退率

共招募了 114 位女性(中位年龄 30岁,范围20-53岁),其中 80 位被确诊为CNI2,34 位为 CIN3。在研究期间,65.8%的女性(75/114)未接受手术治疗FAM19A4/miR124-2 甲基化阴性的女性比 FAM19A4/miR124-2 甲基化阳性的女性表现出更高的临床消退率(74.7% vs 51.3%,p=0.013)。


不同亚组分析的临床消退率

当细胞学检查为意义不明的非典型鳞状细胞/低级别鳞状上皮内病变 (88.4%) 或 HPV16 阴性 (85.1%) 时,FAM19A4/miR124-2 甲基化阴性的女性的消退率最高。

综上,大多数基线 FAM19A4/miR124-2 甲基化阴性的未经治疗的 CIN2/3 可自发临床消退。FAM19A4/miR124-2 甲基化检测与细胞学或 HPV 基因分型相结合,可用于指导 CIN2/3 女性患者选择手术治疗还是随访观察。

 

原始出处:

Wieke W. Kremer, et al. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study). Journal of Clinical Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2105054, encodeId=741a21050541d, content=甲基化, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53281706489, createdName=鲜嫩如花的小春, createdTime=Fri Dec 09 10:02:39 CST 2022, time=2022-12-09, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1774057, encodeId=11941e740572c, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Nov 11 06:52:10 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866599, encodeId=c23718665990a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 13 06:52:10 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408352, encodeId=af53140835257, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri May 13 06:52:10 CST 2022, time=2022-05-13, status=1, ipAttribution=)]
    2022-12-09 鲜嫩如花的小春 来自江西省

    甲基化

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2105054, encodeId=741a21050541d, content=甲基化, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53281706489, createdName=鲜嫩如花的小春, createdTime=Fri Dec 09 10:02:39 CST 2022, time=2022-12-09, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1774057, encodeId=11941e740572c, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Nov 11 06:52:10 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866599, encodeId=c23718665990a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 13 06:52:10 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408352, encodeId=af53140835257, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri May 13 06:52:10 CST 2022, time=2022-05-13, status=1, ipAttribution=)]
    2022-11-11 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=2105054, encodeId=741a21050541d, content=甲基化, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53281706489, createdName=鲜嫩如花的小春, createdTime=Fri Dec 09 10:02:39 CST 2022, time=2022-12-09, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1774057, encodeId=11941e740572c, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Nov 11 06:52:10 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866599, encodeId=c23718665990a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 13 06:52:10 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408352, encodeId=af53140835257, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri May 13 06:52:10 CST 2022, time=2022-05-13, status=1, ipAttribution=)]
    2022-06-13 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=2105054, encodeId=741a21050541d, content=甲基化, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53281706489, createdName=鲜嫩如花的小春, createdTime=Fri Dec 09 10:02:39 CST 2022, time=2022-12-09, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1774057, encodeId=11941e740572c, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Fri Nov 11 06:52:10 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866599, encodeId=c23718665990a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 13 06:52:10 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408352, encodeId=af53140835257, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri May 13 06:52:10 CST 2022, time=2022-05-13, status=1, ipAttribution=)]
    2022-05-13 一闲

相关资讯

IJMI:筛查准确率高达92.1%!大数据助力宫颈癌筛查

来自中国科学院苏州生物医学工程技术研究所的研究团队提出了一种跨膜态融合细胞学检查、HPV检测和阴道镜图像检查结果的宫颈病变无创筛查方法,筛查准确率高达92.1%。

度伐利尤单抗治疗局部晚期宫颈癌III期研究,结果失败

3月24日,阿斯利康宣布,PD-L1单抗Imfinzi (度伐利尤单抗) 联合放化疗(CRT)治疗局部晚期宫颈癌的III期CALLA研究未达到改善无进展生存期(PFS)的主要终点。与单纯放化疗相比,P

WHO最新建议:HPV疫苗只打一针也有效,这些证据很重要!

单剂HPV四价疫苗对其持续感染的保护效力其实与2剂或3剂HPV四价疫苗并无显著差异。

Front Oncol:宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素

研究表明,大多数接受RHND+辅助RT/CCRT治疗的宫颈癌患者在两年内复发。预后因素包括切除切缘、腹主动脉旁及髂总淋巴结转移、DM、复发后未治疗、早期复发等。

J Clin Oncol:信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

信迪利单抗联合安罗替尼作为既往化疗失败的晚期宫颈癌患者的二线或晚线疗法是有效且安全的

NEJM:采用Cemiplimab治疗复发性宫颈癌

经一线含铂化疗方案治疗后复发的宫颈癌患者采用Cemiplimab治疗的生存期显著长于继续单药化疗